Mansi R. Shah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Mansi R. Shah has a total of 224 co-authors. Here are the top co-authors by number of shared publications:
- Carolina Schinke
Myeloma Center, University of Arkansas for Medical Science, Little Rock, USA
4 shared publications - Aishee Bag
Department of Internal Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA
3 shared publications - Aniko Szabo
Medical College of Wisconsin
3 shared publications - Frits van Rhee
Myeloma Center, University of Arkansas for Medical Science, Little Rock, USA
3 shared publications - Glenn S. Kroog
Regeneron Pharmaceuticals Inc., Tarrytown, USA
3 shared publications James E. Hoffman
3 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Springer Nature in Blood Cancer Journal
Infection risk and management in patients with relapsed/refractory multiple myeloma treated with linvoseltamab in the LINKER-MM1 study
- 1 October 2026
- Published by Springer Nature in Blood Cancer Journal
Open AccessInfection risk and management in patients with relapsed/refractory multiple myeloma treated with linvoseltamab in the LINKER-MM1 study
- Open Access
- 22 August 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1)
Prognostic impact of lymphocyte kinetics and immune composition during bispecific antibody therapy in relapsed/refractory multiple myeloma
- 22 August 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1)
Open AccessPrognostic impact of lymphocyte kinetics and immune composition during bispecific antibody therapy in relapsed/refractory multiple myeloma
- Open Access
- 11 June 2026
- Published by Springer Nature in Research Square
The prognostic impact of lymphocyte counts and immune composition in bispecific antibody therapy in relapsed/refractory multiple myeloma
Bispecific antibody (bsAb) therapy has emerged as an effective option for patients with relapsed/refractory multiple myeloma (MM). While it has been shown that efficacy of bsAb therapy heavily relies on T cell fitness, little is known how to capture clinical immune parameters that could be predictive of response to bsAbs. In the present retrospective study we sequentially collected data on absolute lymphocyte count (ALC) in 303 patients over 6 months and further investigated additional data on lymphocyte composition (CD4 and CD8 T cells, CD 19 B cells and CD56 NK cells), which was available in 124 patients. We show that initial ALC, at start of bsAb therapy, is not associated with clinical outcome, however a more rapid and increased ALC expansion over the next 14 days was seen in responders compared to non-responders. Subset analysis revealed that response to bsAb therapy was associated with higher CD4 and CD56 counts and lower CD19 at day 30 compared to non-responders. In a simplified model we show that incorporating CD4/CD8 ratio < 0.5 (1 point), CD19 > 20/µL (2 points), CD56 < 135/µL (1 point) at the 30 day mark post bispecific antibody initiation predicts for long term progression free and overall survival, with higher scores having worsen outcome. Taken together, these findings support the rationale of ALC and T cell subset dynamics serving as accessible surrogate markers of immune competence in patients undergoing bsAb therapy, with potential utility for response prediction.
- 11 June 2026
- Published by Springer Nature in Research Square
Open AccessThe prognostic impact of lymphocyte counts and immune composition in bispecific antibody therapy in relapsed/refractory multiple myeloma
Bispecific antibody (bsAb) therapy has emerged as an effective option for patients with relapsed/refractory multiple myeloma (MM). While it has been shown that efficacy of bsAb therapy heavily relies on T cell fitness, little is known how to capture clinical immune parameters that could be predictive of response to bsAbs. In the present retrospective study we sequentially collected data on absolute lymphocyte count (ALC) in 303 patients over 6 months and further investigated additional data on lymphocyte composition (CD4 and CD8 T cells, CD 19 B cells and CD56 NK cells), which was available in 124 patients. We show that initial ALC, at start of bsAb therapy, is not associated with clinical outcome, however a more rapid and increased ALC expansion over the next 14 days was seen in responders compared to non-responders. Subset analysis revealed that response to bsAb therapy was associated with higher CD4 and CD56 counts and lower CD19 at day 30 compared to non-responders. In a simplified model we show that incorporating CD4/CD8 ratio < 0.5 (1 point), CD19 > 20/µL (2 points), CD56 < 135/µL (1 point) at the 30 day mark post bispecific antibody initiation predicts for long term progression free and overall survival, with higher scores having worsen outcome. Taken together, these findings support the rationale of ALC and T cell subset dynamics serving as accessible surrogate markers of immune competence in patients undergoing bsAb therapy, with potential utility for response prediction.
- Open Access
- 27 March 2026
- Published by Elsevier in Blood Neoplasia
- Vol. 3 (3)
Health-related quality of life with linvoseltamab treatment for relapsed/refractory multiple myeloma in LINKER-MM1
- 27 March 2026
- Published by Elsevier in Blood Neoplasia
- Vol. 3 (3)
Open AccessHealth-related quality of life with linvoseltamab treatment for relapsed/refractory multiple myeloma in LINKER-MM1
- Top Cited PapersOpen Access
- 15 November 2025
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 26 (2) , e201-e212.e8
Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses
- 15 November 2025
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 26 (2) , e201-e212.e8
Top Cited PapersOpen AccessLinvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses
- Top Cited PapersOpen Access
- 7 November 2025
- Published by Springer Nature in Blood Cancer Journal
- Vol. 15 (1) , 1-8
Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study
Talquetamab is a first-in-class GPRC5DxCD3 bispecific antibody approved for heavily pretreated relapsed/refractory multiple myeloma (RRMM), and this multicenter retrospective analysis of 114 RRMM patients treated between October 2023 and January 2025 demonstrated significant efficacy in a heavily pretreated population with median 6 prior therapies. All patients were triple-class refractory, 79% were penta-refractory, and 65% had received prior BCMA-targeted therapy. The overall response rate was 73%, including complete response in 26% and very good partial response in 26%, with six-month progression-free and overall survival rates of 56 and 86% respectively and median progression-free survival of 10 months. Common adverse events included cytokine release syndrome (CRS; 54% with grade ≥2 in 7.3%), infections (27%), and immune effector cell-associated neurotoxicity syndrome (9.8%). The 3-month cumulative infection incidence of 14% for both bacterial and viral infections, where 59% were viral and 41% bacterial, grade ≥3 infections occurred in 18%, and intravenous immunoglobulin was used in 61% of patients. Significant weight loss was observed, with a mean 8.8% decrease at 6 months. This real-world analysis confirms talquetamab’s efficacy in heavily pretreated RRMM while highlighting notable toxicities, including progressive weight loss and infections, which require rigorous monitoring and proactive supportive care.
- 7 November 2025
- Published by Springer Nature in Blood Cancer Journal
- Vol. 15 (1) , 1-8
Top Cited PapersOpen AccessTalquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study
Talquetamab is a first-in-class GPRC5DxCD3 bispecific antibody approved for heavily pretreated relapsed/refractory multiple myeloma (RRMM), and this multicenter retrospective analysis of 114 RRMM patients treated between October 2023 and January 2025 demonstrated significant efficacy in a heavily pretreated population with median 6 prior therapies. All patients were triple-class refractory, 79% were penta-refractory, and 65% had received prior BCMA-targeted therapy. The overall response rate was 73%, including complete response in 26% and very good partial response in 26%, with six-month progression-free and overall survival rates of 56 and 86% respectively and median progression-free survival of 10 months. Common adverse events included cytokine release syndrome (CRS; 54% with grade ≥2 in 7.3%), infections (27%), and immune effector cell-associated neurotoxicity syndrome (9.8%). The 3-month cumulative infection incidence of 14% for both bacterial and viral infections, where 59% were viral and 41% bacterial, grade ≥3 infections occurred in 18%, and intravenous immunoglobulin was used in 61% of patients. Significant weight loss was observed, with a mean 8.8% decrease at 6 months. This real-world analysis confirms talquetamab’s efficacy in heavily pretreated RRMM while highlighting notable toxicities, including progressive weight loss and infections, which require rigorous monitoring and proactive supportive care.
- Open Access
- 17 July 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (19) , 4806-4809
The Efficacy of Teclistamab in Multiple Myeloma Patients with Secondary Plasma Cell Leukemia
- 17 July 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (19) , 4806-4809
Open AccessThe Efficacy of Teclistamab in Multiple Myeloma Patients with Secondary Plasma Cell Leukemia
- Top Cited PapersOpen Access
- 1 August 2024
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 42 (22) , 2702-2712
Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma
PURPOSE: We present a phase I/II first-in-human trial evaluating the safety and efficacy of 50 mg and 200 mg doses of linvoseltamab, a B-cell maturation antigen × CD3 bispecific antibody in relapsed/refractory multiple myeloma (RRMM). METHODS: Phase II eligible patients had RRMM that either progressed on/after ≥three lines of therapy including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 antibody or was triple-class (PI/IMiD/anti-CD38) refractory. Phase II treatment was once a week through week 14 and then once every 2 weeks. Phase II 200 mg patients who achieved a ≥very good partial response by week 24 received linvoseltamab once every 4 weeks. The primary end point in phase II was overall response rate (ORR). RESULTS: Among the 117 patients treated with 200 mg, the median age was 70 years, 39% had high-risk cytogenetics, and 28% had penta-refractory disease. At a median follow-up of 14.3 months, the ORR was 71%, with 50% achieving ≥complete response (CR). In 104 patients treated with 50 mg at a median follow-up of 7.4 months, the ORR was 48%, with 21% achieving ≥CR. The median duration of response (DOR) for 200 mg patients (n = 83) was 29.4 months (95% CI, 19.2 to not evaluable). Among 200 mg patients, the most common adverse events included cytokine release syndrome (35.0% Gr1, 10.3% Gr2, 0.9% Gr3), neutropenia (0.9% Gr2, 18.8% Gr3, 23.1% Gr4), and anemia (3.4% Gr1, 4.3% Gr2, 30.8% Gr3). Immune effector cell-associated neurotoxicity syndrome occurred in 7.7% of patients (2.6% each Gr1, Gr2, Gr3). Infections were reported in 74.4% of patients (33.3% Gr3, 2.6% Gr4); infection frequency and severity declined over time. CONCLUSION: Linvoseltamab 200 mg induced deep and durable responses, with a median DOR of 29.4 months, in patients with RRMM with an acceptable safety profile.
- 1 August 2024
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 42 (22) , 2702-2712
Top Cited PapersOpen AccessLinvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma
PURPOSE: We present a phase I/II first-in-human trial evaluating the safety and efficacy of 50 mg and 200 mg doses of linvoseltamab, a B-cell maturation antigen × CD3 bispecific antibody in relapsed/refractory multiple myeloma (RRMM). METHODS: Phase II eligible patients had RRMM that either progressed on/after ≥three lines of therapy including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 antibody or was triple-class (PI/IMiD/anti-CD38) refractory. Phase II treatment was once a week through week 14 and then once every 2 weeks. Phase II 200 mg patients who achieved a ≥very good partial response by week 24 received linvoseltamab once every 4 weeks. The primary end point in phase II was overall response rate (ORR). RESULTS: Among the 117 patients treated with 200 mg, the median age was 70 years, 39% had high-risk cytogenetics, and 28% had penta-refractory disease. At a median follow-up of 14.3 months, the ORR was 71%, with 50% achieving ≥complete response (CR). In 104 patients treated with 50 mg at a median follow-up of 7.4 months, the ORR was 48%, with 21% achieving ≥CR. The median duration of response (DOR) for 200 mg patients (n = 83) was 29.4 months (95% CI, 19.2 to not evaluable). Among 200 mg patients, the most common adverse events included cytokine release syndrome (35.0% Gr1, 10.3% Gr2, 0.9% Gr3), neutropenia (0.9% Gr2, 18.8% Gr3, 23.1% Gr4), and anemia (3.4% Gr1, 4.3% Gr2, 30.8% Gr3). Immune effector cell-associated neurotoxicity syndrome occurred in 7.7% of patients (2.6% each Gr1, Gr2, Gr3). Infections were reported in 74.4% of patients (33.3% Gr3, 2.6% Gr4); infection frequency and severity declined over time. CONCLUSION: Linvoseltamab 200 mg induced deep and durable responses, with a median DOR of 29.4 months, in patients with RRMM with an acceptable safety profile.
- Open Access
- 14 November 2022
- Published by Springer Nature in Nature Cancer
- Vol. 3 (11) , 1404
Author Correction: Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling
- 14 November 2022
- Published by Springer Nature in Nature Cancer
- Vol. 3 (11) , 1404
Open AccessAuthor Correction: Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling
- 25 August 2022
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 22, S120-S121
P-156: Evaluation of SAVED and IMPEDE-VTE scoring systems for venous thromboembolism prophylaxis in patients with multiple myeloma
- 25 August 2022
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 22, S120-S121
P-156: Evaluation of SAVED and IMPEDE-VTE scoring systems for venous thromboembolism prophylaxis in patients with multiple myeloma